Related Experiment Video
Updated: Feb 4, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle
Aleksandr Shek1, Rano Alieva1, Ravshanbek Kurbanov1
1Republican Specialized Center of Cardiology (RSCC) Ministry of Health of Republic Uzbekistan, Tashkent, Uzbekistan.
Insights
Heterozygous familial hypercholesterolemia (HeFH) in Uzbekistan is linked to increased heart attack and stroke risk due to underdiagnosis and inadequate statin therapy. Genetic analysis of PCSK9 E670G revealed associations with cardiovascular events, highlighting the need for early detection and intensified treatment.
Area of Science:
- Cardiovascular Genetics
- Lipidology
- Public Health Genomics
Background:
- Familial hypercholesterolemia (FH) poses a significant disease burden, particularly in underdiagnosed populations like Uzbekistan.
- Suboptimal lipid management in patients with heterozygous familial hypercholesterolemia (HeFH) correlates with increased cardiovascular event rates.
Purpose of the Study:
- To evaluate the disease burden and molecular genetic characteristics of HeFH patients in the Uzbek population.
- To inform the development of early detection and effective treatment strategies for HeFH.
Main Methods:
- Utilized the Dutch Lipid Clinic Network Criteria (DLCN) for HeFH diagnosis in 201 patients with coronary artery disease.
- Measured serum PCSK-9 levels and performed PCR-RFLP for PCSK9 E670G (rs505151) polymorphism genotyping.
- Compared HeFH patients (n=57) with a control group (n=144), including statin-naïve and statin-treated subgroups.
Main Results:
- HeFH patients exhibited significantly higher rates of myocardial infarction, stroke, and percutaneous coronary intervention compared to controls.
- PCSK9 E670G 'G' allele carriage was more frequent in HeFH patients, associated with increased cardiovascular events and carotid plaque burden.
- Despite statin therapy, HeFH patients showed persistently elevated total cholesterol and LDL-C levels.
Conclusions:
- Early diagnosis, including genetic confirmation, is crucial for managing HeFH in Uzbekistan.
- Intensified statin therapy or combination therapy (statins with ezetimibe) is recommended to achieve target LDL-C levels and prevent major adverse cardiovascular events (MACE).
Background And Aims:
We aimed to assess the disease burden and to study the molecular genetic characteristics of heterozygous familial hypercholesterolemia (HeFH) patients within the Uzbek population to develop a program of early disease detection and effective treatment measures.
Methods:
201 patients were included in the study, of whom 57 with chronic stable coronary artery disease (SCAD) and HeFH, and 144 with SCAD without HeFH belonging to the control group, and divided into two subgroups: A, statin free before the study (n = 63) and B (n = 81), who took statin outpatiently. We applied the Dutch Lipid Clinic Network Criteria (DLCN) to diagnose HeFH. Serum level of PCSK-9 was measured with the ELISA Kit. The genetic typing at PCSK9 E670G (rs505151) polymorphism was performed with the PCR-RFLP method.
Results:
Underestimation of early lipid studies and inadequate treatment in HeHF patients within the Uzbek population are accompanied by a 1.8-time increase of more frequent history of myocardial infarction (p < 0.05), a 3-time stroke (p < 0.05) and 2-time percutaneous coronary intervention (p < 0.05). The study of genotypes and alleles of PCSK9 E670G (rs505151) polymorphism allowed to state that сarriage of the «damaging » allele G in SCAD and HeHF patients was 2 times higher (11.4%), than in non HeHF (6.0%) and 3 times (3.0%) than in healthy ones, but the differences were not significant. Herewith, G-carriership is accompanied by a higher incidence of myocardial infarction (p < 0.05) and stroke (p < 0.05), coronary artery bypass grafting in anamnesis (p < 0.001), and number of plaques in carotids (p < 0.05). In group I of SCAD patients with HeFH, 18 (31.6%) cases of diabetes mellitus were observed, which did not exceed their number in group II (48, 33.3%). However, most of them were carriers of the G allele (82.0%, p < 0.001). Despite treatment with rosuvastatin 20-40 mg/day, in HeHF patients after 3 months, the level of total cholesterol (p < 0.001) and LDL-C (p < 0.001) was significantly higher than in the control group.
Conclusions:
Improvement of early diagnosis of FH, including genetic confirmation, and preventional high-intensity statin therapy or a combination of statins with ezetimibe to achieve the target level of LDL-C, is the closest tactical objective for prevention of MACE within the Uzbek population.
More Related Videos
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
Related Concept Videos
Protein Families
Protein Families
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Gene Families
Family Therapy
Strategic Family Therapy
Strategic family therapy emphasizes resolving communication barriers and improving problem-solving abilities...
Sources of Self-Esteem I: Family Experience